Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)

Tonghua Dongbao Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,320	2,930	2,742	3,219	2,855	2,752
Other Revenue	129.18	145.81	36.47	49.22	37.13	24.7
Revenue	2,449	3,075	2,778	3,268	2,892	2,777
Revenue Growth (YoY)	-11.18%	10.69%	-14.98%	12.99%	4.14%	3.13%
Cost of Revenue	514	621.05	628.13	586.99	582.86	727.15
Gross Profit	1,935	2,454	2,150	2,681	2,309	2,050
Selling, General & Admin	1,099	1,047	1,114	1,255	1,091	1,006
Research & Development	107.32	104.96	146.71	166.86	106.93	78.04
Other Operating Expenses	13.51	11.65	14.57	11.27	-34.35	18.49
Operating Expenses	1,221	1,184	1,268	1,435	1,165	1,108
Operating Income	713.93	1,270	882.29	1,246	1,145	942.39
Interest Expense	-10.72	-5.17	-0.28	-	-10.17	-20.56
Interest & Investment Income	118.55	103.61	942.66	304.32	43.64	47.3
Currency Exchange Gain (Loss)	0.76	0.47	0	0.24	-0.45	0
Other Non Operating Income (Expenses)	-4.66	-1.65	-0.88	0.33	-7.38	-2.07
EBT Excluding Unusual Items	817.85	1,368	1,824	1,550	1,170	967.06
Gain (Loss) on Sale of Investments	1.41	0.52	0.96	-0.37	0.37	-
Gain (Loss) on Sale of Assets	-256.55	-3.13	-0.11	-13.48	-62.44	2.22
Asset Writedown	-70.2	-7	-1.74	-11.53	-	-3.48
Other Unusual Items	11.19	7.91	6.62	9.35	-	-13.3
Pretax Income	503.7	1,366	1,830	1,534	1,108	952.5
Income Tax Expense	51.01	197.97	247.69	225.86	177.81	142.85
Earnings From Continuing Operations	452.69	1,168	1,582	1,309	930.32	809.64
Minority Interest in Earnings	0.24	-0.09	0.06	-0.34	-0.41	1.56
Net Income	452.54	1,168	1,582	1,308	929.92	811.21
Net Income to Common	452.54	1,168	1,582	1,308	929.92	811.21
Net Income Growth	-48.81%	-26.17%	20.92%	40.69%	14.63%	-3.27%
Shares Outstanding (Basic)	1,930	1,979	2,002	2,044	2,022	2,028
Shares Outstanding (Diluted)	1,930	1,979	2,002	2,044	2,022	2,028
Shares Change (YoY)	-3.98%	-1.15%	-2.04%	1.12%	-0.32%	-0.85%
EPS (Basic)	0.23	0.59	0.79	0.64	0.46	0.40
EPS (Diluted)	0.23	0.59	0.79	0.64	0.46	0.40
EPS Growth	-46.69%	-25.32%	23.44%	39.13%	15.00%	-2.44%
Free Cash Flow	227.19	513.4	370.21	579.62	712.69	859.04
Free Cash Flow Per Share	0.12	0.26	0.18	0.28	0.35	0.42
Dividend Per Share	0.250	0.250	0.500	0.300	0.210	0.200
Dividend Growth	0%	-50.00%	66.67%	42.86%	5.00%	0%
Gross Margin	79.01%	79.81%	77.39%	82.04%	79.85%	73.82%
Operating Margin	29.15%	41.31%	31.75%	38.12%	39.57%	33.93%
Profit Margin	18.48%	37.97%	56.93%	40.03%	32.15%	29.21%
Free Cash Flow Margin	9.28%	16.69%	13.32%	17.74%	24.64%	30.93%
EBITDA	899.04	1,455	1,033	1,389	1,299	1,095
EBITDA Margin	36.71%	47.32%	37.20%	42.51%	44.92%	39.44%
D&A For EBITDA	185.12	184.94	151.17	143.65	154.54	152.8
EBIT	713.93	1,270	882.29	1,246	1,145	942.39
EBIT Margin	29.15%	41.31%	31.75%	38.12%	39.57%	33.93%
Effective Tax Rate	10.13%	14.49%	13.54%	14.72%	16.05%	15.00%
Revenue as Reported	2,449	3,075	2,778	3,268	-	2,777
Advertising Expenses	-	63.59	46.79	143.61	120.46	102.05

Source: S&P Capital IQ. Standard template. Financial Sources.